Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography in monitoring therapeutic changes of RNA interference therapeutics in patients with hereditary transthyretin amyloid cardiomyopathy.
Hung YH, Yu AL, Chen YC, Tsai CH, Su MY, Shun CT, Hsueh HW, Jyh-Ming Juang J, Lee MJ, Tseng PH, Hsu CH, Hsieh ST, Ko CL, Lin KP, Yu WC, Cheng MF, Chao CC, Lin YH. Hung YH, et al. Among authors: chao cc. J Formos Med Assoc. 2024 Oct 10:S0929-6646(24)00481-9. doi: 10.1016/j.jfma.2024.10.005. Online ahead of print. J Formos Med Assoc. 2024. PMID: 39389803 Free article.
Estimating the Seroprevalence of Scrub Typhus in Nepal.
Linsuwanon P, Auysawasdi N, Chao CC, Rodkvamtook W, Shrestha B, Bajracharya S, Shrestha J, Wongwairot S, Limsuwan C, Lindroth E, Mann A, Davidson S, Wanja E, Shrestha SK. Linsuwanon P, et al. Among authors: chao cc. Pathogens. 2024 Aug 29;13(9):736. doi: 10.3390/pathogens13090736. Pathogens. 2024. PMID: 39338927 Free PMC article.
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA; ADHERE Study Group. Allen JA, et al. Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0. Lancet Neurol. 2024. PMID: 39304241 Clinical Trial.
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.
Conceição I, Berk JL, Weiler M, Kowacs PA, Dasgupta NR, Khella S, Chao CC, Attarian S, Kwoh TJ, Jung SW, Chen J, Viney NJ, Yu RZ, Gertz M, Masri A, Cruz MW, Coelho T. Conceição I, et al. Among authors: chao cc. J Neurol. 2024 Oct;271(10):6655-6666. doi: 10.1007/s00415-024-12616-6. Epub 2024 Aug 13. J Neurol. 2024. PMID: 39138650 Free PMC article. Clinical Trial.
689 results